Researchers at Johns Hopkins University have identified a blood-based biomarker that could enable early detection of pancreatic cancer, one of the deadliest forms of the disease. The biomarker, a specific protein fragment found in circulating exosomes, was detected in patients up to 18 months before conventional diagnosis.
In a study of 1,200 participants, the test demonstrated a sensitivity of 89 percent and a specificity of 92 percent, far exceeding the accuracy of current screening methods. The researchers say a simple blood draw could be incorporated into routine checkups for high-risk individuals.
Pancreatic cancer has a five-year survival rate of just 12 percent, largely because it is typically diagnosed at advanced stages. The research team is now working with diagnostic companies to develop a commercial test, with clinical validation trials expected to begin later this year.
